Activation of phospholipase D (PLD) occurs in response to various stimuli and results from the activity of two isozymes, hPLD1 and hPLD2. PLD activity appears to be involved in several myeloid cell processes during their development and activation, including proliferation of myeloblasts in the bone marrow and secretion, phagocytosis and NADPH oxidase activation, essential functions of differentiated neutrophils. The present work studies PLD characteristics, activity and both isozyme expression during maturation and differentiation of myeloid cells by using three different systems: leukemic myeloblasts at different stages of maturation, terminally differentiated neutrophils ex vivo and four human myeloid cell lines, NB4, HL-60, PLB 985 and U937, induced to differentiate with alltrans retinoic acid (ATRA), a cyclic adenosine monophosphate (cAMP) analogue or both agents together. HL-60, a bipotential cell line has also been differentiated along the granulocytic pathway with DMSO and the monocytic pathway with 1,25-dihydroxy vitamin D3. In all these systems, PLD activity increases with maturation and differentiation whatever the inducer used and the granulocytic or monocytic pathways. Increase in basal activity which reflects the expression during development of both hPLD1 and hPLD2 appears to be mainly related to the former isozyme expression. Association of PLD characteristic changes with maturation and differentiation was also confirmed using two NB4 clones resistant to these processes. Comparison between PLD characteristics in myeloblasts during maturation and differentiation ex vivo and in vitro in the different cell lines demonstrated that NB4 induced to differentiate with ATRA represents the best model for further studies on the specific roles of each PLD isoform in various functions of differentiated myeloid cells.
Introduction
Early myeloid cells are able to proliferate along the pathway of maturation. Upon maturation, they lose this capacity and differentiate mainly into neutrophils, and to a lesser extent into monocytes. Fully differentiated myeloid cells possess several properties linked to their final role: prevent infection. Indeed, they are able to ingest and destroy microorganisms. 1 Acute myeloblastic leukemia (AML) is due to abnormal proliferation of myeloid cells blocked at a specific stage of maturation and differentiation classified from M0 to M5 according to the FAB leukemia subtype nomenclature. AML is a frequent disease which still has a serious prognosis. For several years, patients suffering from M3 promyelocytic leukemia have been treated with a high rate of remission with all-trans retinoic acid (ATRA), a differentiating agent which forces leukemic cells to differentiate, acquire new functions and stop proliferation. 2, 3 Understanding the events taking place during the complex process of maturation and differentiation is important for the development of AML therapies.
Over the past two decades, phospholipase D (PLD) has been well documented to play an essential role in signal transduction in a large variety of mammalian cells. 4 Its activation leads to hydrolysis of phosphatidylcholine, producing choline and phosphatidic acid (PA), a phospholipid recognized as a second messenger (see review Ref. 5) . Two PLD isoforms have been cloned in human cells 6, 7 and were shown to be differently expressed in most mammalian cell types and tissues. 8, 9 During the past few years, many studies have been focused on PLD activity which indicate that this enzyme activity might be involved in numerous physiological processes of myeloid cells, such as proliferation, differentiation, phagocytosis, secretion and NADPH oxidase activation (see review Ref. 4) . Moreover, in mammals, myeloid cells appear to be amongst the richest in both PLD isozyme mRNAs. 8 Despite major interest in the understanding of the relative participation of each PLD isoform in physiological processes, their respective roles in myeloid cell functions are still unknown.
To get an insight on PLD changes during myeloid maturation and differentiation, the levels of PLD activity and PLD isoform expression were measured during these processes. This study was performed in ex vivo circulating human leukemic myeloblasts at different maturation and differentiation and in four different myeloid cell lines established in vitro from patients sufferring from different AML subtypes. HL-60 cells now recognized to be established from an AML stage M2 (M2) 10 and NB4 from a M3 AML carrying a t(15;17) translocation 11 can be induced to differentiate towards neutrophillike cells in the presence of all-trans retinoic acid (ATRA) and/or a cyclic AMP analogue. PLB 985 (M4) and U937 (histiocytic), already irreversibly induced toward the monocytic lineage, differentiate towards monocytes in the presence of ATRA.
In the present work, PLD activity and PLD isoform expression were studied in parallel upon maturation and differentiation in ex vivo human leukemic myeloblasts and in several myeloid cell lines induced to mature and differentiate in vitro.
Materials and methods
RPMI-1640 and medium 199 were purchased from Gibco BRL (Paisley, UK). Fetal bovine serum was from Dutcher (Vilmorin, France). Alkyl-sn-glyceryl-3-phosphorylcholine, 1-0-[alkyl-1Ј2Ј- 3 H]-, (30-60 Ci/mmol) (lyso-PAF), phosphatidylcholine were obtained from NEN (Boston, MA, USA). fMLP, phorbol 12-myristate 13-acetate (PMA), dibutyryladenosine3Ј:5Ј-cyclic monophosphate (dibutyryl-cAMP), dibutyryl-cAM8-(4-chlorophenylthio)adenosine cyclic 3Ј,5Ј-monophosphate (8-CPT-cAMP), dimethyl sulfoxide (DMSO), all-trans retinoic acid (ATRA), 1,25-dihydrocholecalciferol (1␣,25-dihydroxy vitamin D3), cytochrome C, nitro-blue tetrazolium (NBT), Hank's and HEPES buffers were purchased from Sigma (St Louis, MO, USA). Ficoll-Hypaque Plus was from Pharmacia Biotech (Upsala, Sweden). RNase protection kit, protease and fatty acid-free bovine serum albumine (BSA), protease inhibitor cocktail (Complete) was purchased from BoehringerMannheim (Mannheim, Germany). Transfer PVDF membranes were purchased from Amersham (UK). Silica gel 60 plates for thin layer chromatography (TLC) analysis were obtained from Whatman (Maidstone, UK). Scintillant liquid, Optiphase 'HiSafe' 3, was from EG&G Wallack (Turku, Finland).
Purification of human neutrophils, monocytes and leukemic cells
Protocol on human cells were approved by the CCPPRB (Comité Consultatif pour la Promotion des Recherches en Biologie). Informed consent was obtained from all blood donors and patients.
Neutrophils were isolated from venous blood of five healthy blood donors. The platelet-rich plasma was first removed. Neutrophils and monocytes were isolated by dextran sedimentation and Ficoll-Hypaque centrifugation. Neutrophils present in the pellet were further purified by elimination of contaminating erythrocytes by hypotonic shock. Purified neutrophils were resuspended in HBSS containing 20 mM HEPES, pH 7.4, 0.1% fatty acid-free BSA, and 5.6 mM glucose. Cell viability was measured by trypan blue exclusion and was greater than 95%. Peripheral blood monocytes present with other monocytic cells at the interface of the gradient were separated from lymphocytes by adhesion to plastic for 2-3 h and recovered for further processes by a 10-min incubation with EDTA.
Peripheral blood mononuclear cells (PBMC) of 12 leukemic patients were collected between November 1995 and March 1998 before the initiation of chemotherapy. The PBMC were separated from total blood samples of patients with hyperleukocytosis (WBC Ͼ10 × 10 9 /l) by Ficoll-Hypaque gradient (Pharmacia Biotech) and frozen in 10% DMSO, 10% human AB serum. All the PBMC samples contained a majority of tumor cells with less than 10% residual lymphocytes or normal hematopoietic cells.
Cell culture and induction of differentiation
NB4 cell line and two RA-resistant clones, NB4-R1and NB4-R2, were obtained from Dr Michel Lanotte (Inserm-CNRS, Paris, France). All other myeloid cell lines, HL60, PLB-985 and U-937 cells purchased from ATCC (USA) were cultured at 37°C in RPMI 1640 supplemented with 10% fetal bovine serum, penicillin (100 IU/ml) streptomycin (100 g/ml) and Lglutamine (2 mM).
Differentiation of NB4 cells and both clones, was initiated by the addition of 1 M ATRA or the combination of 1 M ATRA and 200 M 8-CPT-cAMP. HL-60 cells were induced to differentiate towards neutrophils by addition of 1 M ATRA or 500 M dibutyryl-cAMP as described by Breitmann and Chaplinski, respectively 12, 13 and towards monocytes in the presence of 100 M 1,25-dihydroxy vitamin D3. PLB-985 and U937 cells were differentiated with 1 M ATRA.
Leukemia

NBT reduction
Cell maturation was estimated by nitroblue tetrazolium (NBT) reduction and by morphological changes after cellular staining with May-Grü nwald-Giemsa. Determination of NBT reduction was performed by incubation of 10 6 cells in 1 ml fresh culture medium for 20 min at 37°C with 0.1% NBT and 0.3 M PMA. The percentage of cells containing intracellular blue-black formazan deposits was then determined. At least 200 cells were examined.
Superoxide ion production assay
NADPH oxidase activity was determined by using the reduction of cytochrome C by O 
Determination of phospholipase D activity in intact cells
PEt measurement:
PLD activity was measured in intact cells as previously described.
14 Briefly, after washing, cells were labelled for 30 min at 37°C with 3 H-lyso-PAF (2 Ci/ml) in an isotonic medium buffered with Hepes, pH 7.4. After 10 min preincubation in the same medium containing 1.5% ethanol, PLD activity measurement was performed using 10 6 cells (100 l aliquots). The enzymatic reaction was stopped after 10 min incubation at 37°C by addition of 500 l of chloroform/methanol (1:1, v/v) and samples were processed as previously reported. 14 
RNase protection assay
Total RNA was isolated from cell lines, leukemia cells and neutrophils using Qiagen's RNeasy kit according to manufacturer's instruction (Qiagen, Hilden, Germany).
Probes were made of a 398 nt hPLD1 cDNA fragment (nt 382-780) and a 360 nt hPLD2 cDNA fragment (nt 2094-2454). Ribonuclease protection was performed as described in the manufacturer's kit. An anti-sense labelled probe RNA was obtained from the in vitro transcription of each linearized plasmid using T7 RNA polymerase. Total RNAs (5 g for PLD1 and 20 g for PLD2) were hybridized with approximatively 30 000 c.p.m. of radiolabelled probe overnight at 45°C. Digestion conditions were 4 g/ml RNase A and 20 U/ml RNase T1 for 30 min at 30°C. Protected fragments were purified by proteinase K digestion, phenol-chloroform extraction, and ethanol precipitation. Purified samples were then separated on 7 M urea sequencing gels. Glyceraldehyde-3-phosphate dehydrogenase (GADPH) was observed not to vary upon maturation and differentiation (unpublished results), and was used for normalization. Results were quantified using a phosphorimager (Moldyn, Cambridge, MA, USA).
Leukemia
Immunoprecipitation and Western blot analysis
Cells (6 × 10 7 cells/ml) were washed with PBS and solubilized on ice for 15 min in lysis buffer: Tris-HCl (50 mM), pH 7.4, NaCl (150 mM), MgCl 2 (1.5 mM), EGTA (5 mM), 10% glycerol, 1% triton X-100, NaVO 4 (2 mM), phenylmethylsulfonyl fluoride (1 mM), aprotinin (5 g/ml), leupeptin (5 g/ml) and centrifuged at 10 000 g for 10 min at 4°C. The resulting supernatants were directly immunoanalyzed by Western blotting for their content in PLD2 and after immunoprecipitation with anti-PLD1 antiserum as described. 15 Labelling was performed as described in the ECL protocol. Immunoreactive bands were scanned and intensity was quantified using a computerized program (ImageQuant).
Results
In vivo, maturation and differentiation of myeloid leukemic cells are associated with a marked increase in PLD activity and a differential increase in each PLD messenger expression
Myeloblasts were obtained from the peripheral blood of patients sufferring from AML at different stages of maturation and differentiation, using the FAB leukemia subtype nomenclature. Changes concerning PLD characteristics during these processes were analyzed. As reported in Figure 1A , intrinsic PLD activity was found to increase with cell maturation and differentiation from stage M0 to M5. M0 to M3 leukemic cells are arrested at stages of maturation which precede commitment towards PMN or monocyte, whereas M4 and M5 myeloblats are already committed to monocytic differentiation.
To study if such variations could be related to an increase in PLD expression, mRNA expression of both isoforms was estimated using RNAse protection, a sensitive measurement technique. As reported in Figure 1b and c, mRNA expression of hPLD1 and hPLD2 was increased according to the stage of maturity and differentiation of the leukemic myeloid cells from M0 to M5, hPLD1 being more increased than hPLD2 (Figure 1b and c). Differences observed in the expression of both PLD isoform messengers might explain the difference in basal PLD activity.
In vivo differentiation of all myeloid cells, whatever their final commitment appears to involve modifications concerning PLDs which might be important for specific functions in differentiated myeloid cells.
Studies on maturation and differentiation have been restricted for years by the availability of ex vivo myeloid cells. At present, several human myeloid cell lines have been established in continuous culture from patients suffering from AML and represent interesting tools for such studies. Thus, we studied the development of PLD activity and changes in expression of PLD1 and PLD2 RNA messengers and proteins in in vitro established myeloid cell lines.
The NB4 cell line acquires neutrophil-like functions upon maturation and differentiation
The NB4 cell line, established from malignant M3 promyelocytes, is a model to study maturation and differentiation towards cells presenting neutrophil-like characteristics. Indeed, ATRA, used for the treatment of patients with acute M3 PLD activity and PLD isoform mRNA expression in relation to maturation stage in leukemic myeloid cells ex vivo. Cells isolated as described in the Methods section were rapidly thawed, washed in PBS at 37°C and preincubated in complete RPMI 1640 medium for at least 4 h before use. More than 90% of cells were alive in such condition. Cells were labelled for 30 min with 3 H-lyso-PAF (2 Ci/ml), washed and preincubated at 37°C for 10 min in an isotonic medium buffered with HEPES, pH 7.4 containing 0.1% BSA. Intrinsic PLD activity was then measured in intact cells over a 20 min at 37°C in the presence of 1.5% ethanol. PLD activity was estimated as amount of radioactivity incorporated into phosphatidylethanol (PEt), expressed as the percentage of phosphatidylcholine (PC) hydrolysed. All determinations were carried out in duplicate. Results are the mean ± s.e. obtained from triplicate aliquots of circulating myeloblasts from three different patients with AML at the same maturation stage. UTPlabelled human PLD1, PLD2 and GADPH probes were hybridized to RNA extracted from myeloblasts isolated from patients with AML at different stages of maturation. Five g of RNA were used for PLD1 (a) and 20 g of RNA for PLD2 (b) RNAse protection assays, respectively. All determinations were carried out on cells from two or three different patients. Results were estimated as the ratio of GADPH mRNA level and the amount of each isoform in immature M0 myeloblasts was considered as equivalent to 1. leukemia, induces differentiation of NB4 cells towards neutrophil-like cells in 4-5 days. Association of ATRA and 8-CPTcAMP also allows the NB4 cell line to mature and differentiate; both inducers together having a more rapid effect than ATRA alone as full differentiation is obtained within 2-3 days. 16 In the present work, we checked that this was the case in our hands as measured by the percentage of cells reducing NBT, a good index for cell maturation. A maximal percentage of NBT-positive cells was obtained after 4 days in the presence of ATRA and after 2 days in the presence of ATRA plus 8-CPT-cAMP (Figure 2a and b) .
A second index of maturation and differentiation towards neutrophil-like cells is the acquisition of a functional NADPH oxidase that can be activated either nonspecifically with PMA or specifically via fMLP receptors. As shown in Figure 2c and 
Figure 3
Time-course of intrinsic PLD activity in NB4 cells upon differentiation. Basal PLD activity in intact NB4 cells was measured upon differentiation with ATRA (a) or with ATRA plus 8-CPT-cAMP (b) as detailed in Figure 1 . Results are the mean ± s.e. of three different experiments in which all determinations were made in duplicate and are expressed as in Figure 1 .
Leukemia d, undifferentiated cells were unable to generate superoxide ions. After induction of differentiation both stimuli provoked superoxide ions generation. Indeed, within 20 s, fMLP led to the production of superoxide ions, maximal after 5 min and reaching a level similar to that produced by normal neutrophils (data not shown). By contrast, PMA gave rise to superoxide ions generation after a 90 s delay which was prolonged for 30 to 40 min (data not shown). fMLP-and PMA-induced production of superoxide ions increased with differentiation as reflected by the percentage of NBT-positive cells. In cells differentiated for 5 days with ATRA (Figure 2c) , stimulation of NADPH oxidase with PMA was greater than in cells differentiated for 3 days with ATRA and 8-CPT-cAMP (Figure 2d) .
Thus, NB4 cells were found to acquire in vitro essential functions of differentiated neutrophils. Therefore, we studied whether we would find in this cell line similar changes in PLD activity and isozyme expression observed in leukemic cells.
Figure 4
Expression of PLD1 and PLD2 RNA messengers in NB4 cells upon differentiation. Human PLD1 and PLD2 and GADPH probes were hybridized to RNA extracted from NB4 cells, at different days after induction of differentiation with ATRA (a and c) or ATRA plus 8-CPT-cAMP (b and d). PLD1 mRNA (a and b) and PLD2 mRNA (c and d) were quantified using RNAse protection assays as detailed in Figure 1 . All determinations were carried out on three different occasions and results are the mean ± s.e.
Figure 5
Expression of PLD1 and PLD2 proteins in NB4 resistant clones upon differentiation. NB4 cells were either undifferentiated or differentiated into neutrophil-like cells for different periods in the presence of ATRA (a and c) or ATRA plus 8-CPT-cAMP (b and d). PLD1 (a and b) and PLD2 (c and d) proteins were detected in cellular extracts from NB4 and quantified by densitometry. All determinations were carried out on three different cell lysates and results are the mean ± s.e.
In vitro maturation and differentiation of NB4 cells with ATRA or ATRA plus 8-CPT-cAMP is accompanied by an increase in PLD activity
Intrinsic PLD activity was studied in the NB4 cell line induced to differentiate with ATRA alone or in combination with 8-CPT-cAMP. When ATRA was the sole inducer, PLD activity increased after a 2 day delay and reached a maximal level within 5 days (Figure 3a) . When both inducers were used together, no delay was observed in PLD activity increase which was progressive and maximal after 3 days (Figure 3b) .
Expression of PLD1 and PLD2 messengers and proteins increases upon in vitro maturation and differentiation of NB4 cells with ATRA or ATRA plus 8-CPT-cAMP
PLD1 mRNA expression was not modified for the first 24 h following ATRA addition (not shown) and increased after 2 days to give a dramatic change when full maturation was reached (Figure 4a ). When ATRA was added with 8-CPTcAMP, an increase in PLD1 messenger expression was progressively obtained and reached a similar level within 3 days to that obtained with ATRA alone (Figure 4b ). PLD2 mRNA expression also increased with differentiation whichever the inducer(s) used but to a lesser extent than PLD1 (Figure 4c and d), reproducing results obtained with patients myeloblasts.
Since PLD activity is related to protein expression, we quantified the cell lysate content of each isoform along the differentiation process. As suspected from mRNA levels, expression of the PLD1 isoform increased with maturation and differentiation (Figure 5a and b) . In similar conditions, PLD2 protein expression increased but to a lesser extent than PLD1 (Figure 5c and d) .
Increased expression of both proteins during this process could reasonably be considered as responsible for the observed increase in intrinsic PLD activity. Although changes in PLD characteristics observed during in vitro-induced differentiation in the NB4 cell line appear to be similar to those observed upon in vivo maturation and differentiation of neutrophils, it cannot be excluded that the inducers used in vitro might be responsible for PLD modifications without any PLD activity in R1-NB4 and R2-NB4 clones resistant to maturation and differentiation and messenger RNA and protein expression of PLD isozymes in R1 NB4 clone. PLD activity (a) was measured in R1 (empty bars) and R2 (hatched bars) clones derived from the NB4 cell line which are resistant to ATRA-and ATRA plus 8-CPT-cAMP-induced differentiation, respectively. Cells were treated with ATRA (1 M) for 4 days, or by ATRA plus 8-CPT-cAMP (0.2 mM) for 3 days and intrinsic PLD activity was estimated as in Figure 1 . mRNA expression of PLD1 (b) and PLD2 (c) and protein expression of PLD1 and PLD2 (d and e, respectively) were estimated in ATRA-and ATRA plus 8-CPT-cAMPdifferentiated cells as indicated. mRNA and protein isozyme measurements were carried out as in Figures 2 and 5. relationship to these processes. Thus, we took advantage of two NB4 clones resistant to induction of differentiation with ATRA or ATRA plus 8-CPT-cAMP 16, 17 to determine whether PLD changes were linked to these physiological processes.
Changes in PLD activity and PLD expression are associated with the process of differentiation
As reported in Figure 6a , intrinsic PLD activity was not different in ATRA-resistant clones, R1 or R2, treated only with this inducer for 5 days. When each clone was cultured with ATRA plus 8-CPT-cAMP for 3 days, a dramatic increase in PLD activity was observed in R1 cells whereas no modification occurred in the non-inducible R2 clone. In parallel, changes Leukemia in PLD isoform messenger and protein expression occurred only in cells susceptible to differentiation, ie in clone R1 induced to mature and differentiate with ATRA plus 8-CPTcAMP. Within 3 days, a major increase in hPLD1 mRNA expression occurred (Figure 6b ) and a lesser increase in hPLD2 mRNA (Figure 6c ). Both protein isozymes were also increased (Figure 6d and e) . In contrast, no modification was observed in the levels of either isoform mRNA in clone R1 cultured with RA alone, nor in clone R2 under all conditions studied (data not shown).
From the present study, the NB4 cell line appears to be a good model for PLD studies during maturation of myeloid cells. However, other myeloid cell lines have been established and also differentiate in vitro. Thus, we compared such lines with NB4 cells and circulating human neutrophils ex vivo. PLD activity and protein expression of PLD isozymes in HL-60 cells after differentiation into granulocyte-and monocyte-like cells with several inducers. PLD activity was measured as PEt formed in HL-60 cells (a, empty bars). Differentiation towards granulocytelike cells was induced with ATRA (1M), DMSO (1.2%) for 4 days or dibutyryl-cAMP (0.5 mM) for 3 days and towards monocyte-like cells with 1,25-dihydroxy vitamin D3 (0.1 M) for 4 days. Intrinsic PLD activity was estimated as in Figure 1 ; determinations were carried out on three different occasions and results are the mean ± s.e. PLD1 (b) and PLD2 (c) proteins were detected in cellular extracts from undifferentiated and differentiated HL-6O cells and quantified by densitometry as in Figure 5 .
Increases in intrinsic PLD activity and in both isoform messenger expressions are common features upon maturation and differentiation in myeloid cell lines and in ex vivo human myeloid cells
Intrinsic PLD activity has been studied in three other cell lines established from AML at various maturation states. In all cell lines, PLD activity and PLD isoform mRNAs expression were measured before and after differentiation with ATRA and/or cAMP analogues. In undifferentiated cells, intrinsic PLD activity was found to be higher in PLB 985 (M4) and U937 (promonocytic) cell lines than in HL-60 (M2) and NB4 (M3) cells (Table 1) . Upon differentiation with ATRA, intrinsic PLD activity was only slightly increased in the two mature cell lines (PLB 985 and U937) to reach the level of PLD activity present in mature neutrophils after differentiation. In contrast, intrinsic PLD activity was strongly increased with maturation and differentiation in HL-60 and NB4 cells (Table 1) . After differentiation, PLD isoform mRNAs were increased in all cell lines studied and the increase in PLD1 mRNA was more marked than that of PLD2 mRNA. Indeed, PLD1 messengers increased 3.5 to 5.5 times in these three cell lines, whereas the PLD2 messengers only increased 1.5 to 2.8 times. Moreover, the increase in each messenger isoform was somewhat less marked upon differentiation in PLB 985 and U937 (around three-to four-fold increase for PLD1 and 1.5-1.8-fold increase for PLD2 messengers) than in HL-60 (5.5-and 2.8-fold increase, respectively) or NB4.
HL-60 cell line can be differentiated towards granulocyteor monocyte-like cells depending on the inducer used. In this cell line, intrinsic PLD activity and PLD isoform expression were estimated after differentiation towards neutrophils in the presence of ATRA, dibutyryl-cAMP or DMSO or towards monocytes with 1,25-dihydroxy vitamin D3. Measurements were performed after 4 days in the presence of each inducer except for dibutyryl-cAMP which induced full differentiation in 3 days. Maturation and differentiation generated by all inducers led to an increase in intrinsic PLD activity (Figure 7a ). PLD1 level was increased upon differentiation whichever the differentiating agent used. In contrast, in this cell line, PLD2 expression was differently expressed depending on the inducer used for differentiation. ATRA did not modify PLD2 protein expression, while DMSO increased it and cAMP provoked a diminution. Differentiation towards monocyte-like cells generated with 1,25-dihydroxy vitamin D3 also decreased this isozyme expression. Thus, in myeloid cells, maturation and differentiation, whichever the granulocytic or monocytic pathway appear to be accompanied by an increase in intrinsic PLD activity, which is likely to be essentially related to PLD1 isoform expression.
PLD activity in fully differentiated human myeloid cells: circulating neutrophils and monocytes
In vivo, myeloid cells differentiate in the bone marrow. In blood, neutrophils and monocytes represent fully differentiated cells with specific functions. Thus, PLD activity was also studied ex vivo in neutrophils and monocytes isolated from healthy donors. A high basal PLD activity was observed in these cells representing about four times that in M2 or M5 circulating myeloblasts. Moreover, in polymorphonuclear neutrophils which are abundant, PLD1 and PLD2 mRNA content could be measured and were found to represent 2.5 and 1.4 times, respectively, the amount measured in M2 cells.
Discussion
A role for PLD activity in cell maturation and differentiation has been suggested but, so far, is poorly documented. The present work is the first demonstration that maturation and 3, 19 Therefore, it could be of interest in these patients to examine PLD activity and isozyme expression in neutrophils and monocytes. Moreover, changes in PLD activity and/or in PLD isoform expression in neutrophils could be an important feature for understanding neutrophil functions during severe infections or major inflammatory reaction and might suggest a new drug target for affecting neutrophil function.
Using four different myeloid cell lines established from human leukemic cells representing different stages of maturation and differentiation, we confirmed that PLD activity and expression of both isoforms also increased with maturation and differentiation. Indeed, HL-60 and NB4 cell lines, established from M2 and M3 AML respectively, contained less intrinsic PLD activity than those derived from M5 and histiocytic leukemias, PLB 985 and U935, respectively. Moreover, in vitro differentiation also promotes an increase in PLD activity and in mRNA expression of both isoforms in the four cell lines. In NB4 cells, we show for the first time that the increase in mRNA expression of each PLD isozyme is translated into increased amounts of PLD1 and PLD2 proteins. In the present work, resistant clones, R1 and R2, nonresponsive to particular inducers were essential tools to ascertain the relationship between PLD development and myeloid cell maturation and differentiation and to discard a role for the agent used to induce differentiation in PLD changes.
A previous study by Nakashima et al 20 showed that upon granulocytic differentiation of HL-60 with ATRA or dibutyrylcAMP, PLD2 mRNA was increased 20-fold and PLD1 only 4-7-fold as measured by RT-PCR. Differences between the results of that study and our own might be due to diffferent sublines used in each laboratory or to different techniques used for mRNA measurements. The latter hypothesis is more likely as we observed that in the four cell lines studied and in circulating leukemic myeloblasts studied ex vivo, the increase of PLD1 mRNA was more marked than the increase of PLD2 mRNA during maturation and differentiation. mRNA expression of the two PLD isozymes has been investigated during differentiation in several tissues and cell types. In rat Leukemia brain, PLD1 mRNA expression, but not that of PLD2, was shown to be markedly increased during embryonic development. 21 Similarly, a major increase in mRNA expression of PLD1 was only observed during 1,25-dihydroxyvitamin D3-induced differentiation in epidermal keratinocytes. 22 Differentiation of PC12 cell was reported to lead to an increase in PLD mRNA which concerns both isoforms or only PLD1 according to the inducer used, cAMP and nerve-growth factor, respectively. 23 Yoshimura et al 24 observed that differentiation of C6 glioma cells provoked a transient increase in PLD1 RNA messenger expression and a major decrease in PLD2 mRNA in response to dibutyryl cAMP and theophilline. In F9 teratocarcinoma cells, PLD1 protein expression was measured and found to be either not changed when cells were differentiated into visceral endoderm in response to ATRA or majorly decreased when differentiation was induced by ATRA plus dibutyryl-cAMP into parietal endoderm. 25 Although the amount in mRNA of one or both isoform was modified in all studies, increases and/or decreases were observed during differentiation suggesting different roles for PLD isoforms expression/activity in the different cell types.
The major effect for PLD activity seems to be production of phosphatidic acid (PA) which acts as a second messenger. 5 This minor and transiently formed phospholipid, shown to be involved in PI4,5P 2 synthesis, 26, 27 appears to be essential for PLD activity which requires this polyphosphoinositide for its activity. 28 PA production has also been demonstrated to be essential for adhesion, 29 granule secretion and NADPH oxidase activation, 30 functions essential for neutrophil migration to the site of infection and for bacteriostatic and bacteriolytic activities.
So far, upon differentiation of myeloid cells, it has been reported that increased PLD activity was reponsible for the activation of cPLA2 in U937. 31 In contrast, HL-60 cell differentiation induced with two different agents, ATRA and PMA was previously shown to decrease the activity of another phospholipase, PIP 2 -PLC. [31] [32] [33] The specific roles of each PLD isoform in the functions of differentiated myeloid cells are not yet documented. However, levels of PLD1 after HL-60 maturation and differentiation with several inducers suggest that this isoform might be that required for neutrophil and monocyte functions. Neutrophils are abundant in the peripheral blood however their half-life is short (24 h), moreover they contain high levels of proteases, two properties which render work with this human material more difficult. In contrast, monocytes have a longer half-life, but their number in peripheral blood is low. Therefore, for functional studies, it is interesting to utilize a myeloid cell line able to acquire most properties of mature differentiated cells in vitro. Several myeloid cell lines established from AML at various stages are known to differentiate in vitro. They produce neutrophil-like or monocyte-like cells and thus, represent useful tools for futher studies on PLD providing that their isozyme characteristics are close to those in ex vivo cells. Our results concerning PLD in four myeloid cell lines and in ex vivo myeloid cells indicate that NB4 would be a good model to study further the roles of PLD isoforms during maturation, differentiation and in the functions of neutrophil-like cells. In this cell line, ATRA appears to be the best granulocytic inducer for development of PLD characteristics close to those of neutrophils. Moreover, its maturation and differentiation with this agent also lead to expression of fMLP receptors and lactoferrin expression located in specific granules. 34 Major differences were observed between NB4 and HL-60 in the level of PLD2 protein isoform but not in mRNA. This discrepancy might be due to differences in RNA protease development between these two cell lines along the pathway of maturation and differention.
In conclusion, we have demonstrated that leukemic myeloid cells possess two different PLD isozymes whose expression increases with maturation and differentiation. Although, PLD activity is known to be involved in specific functions of differentiated myeloid cells, little is known, so far, about the respective participation of the two PLD isozymes in these functions. It seems likely that each of them is important for different physiological processes in relation to their specific regulation and/or subcellular localization. However, is each specific PLD isoform responsible for certain functions? Do they both participate in the same functions but in different subcellular locations? More work is required to answer these questions. The NB4 cell line appears to be a good model to fully understand the relative participation of PLD1 and PLD2 isoforms in myeloid cell functions that require PLD activity.
